Angiotensin II acetate

CAS No. 68521-88-0

Angiotensin II acetate( Angiotensin II human acetate,Ang II acetate,DRVYIHPF acetate )

Catalog No. M22272 CAS No. 68521-88-0

Angiotensin II acetate is a vasoconstrictor that mainly acts on the AT1 receptor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 30 In Stock
10MG 49 In Stock
25MG 110 In Stock
50MG 208 In Stock
100MG 316 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Angiotensin II acetate
  • Note
    Research use only, not for human use.
  • Brief Description
    Angiotensin II acetate is a vasoconstrictor that mainly acts on the AT1 receptor.
  • Description
    Angiotensin II acetate is a vasoconstrictor that mainly acts on the AT1 receptor.(In Vitro):Most of the known actions of Angiotensin II (Ang II) human acetate are mediated by AT1 receptors, the AT2 receptor contributes to the regulation of blood pressure and renal function.Angiotensin II human acetate raises blood pressure (BP) by a number of actions, the most important ones being vasoconstriction, sympathetic nervous stimulation, increased aldosterone biosynthesis and renal actions. Other Angiotensin II human acetate actions include induction of growth, cell migration, and mitosis of vascular smooth muscle cells, increased synthesis of collagen type I and III in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. These actions are mediated by type 1 Ang II receptors (AT1).Angiotensin II (1 nM) induces the expression of LOX-1 and VEGF and enhances capillary formation from human coronary endothelial cells in Matrigel assay. Angiotensin II -mediated expression of LOX-1 and VEGF, capillary formation, intracellular reactive oxygen species generation, and phosphorylation of p38 as well as p44/42 mitogen-activated protein kinases, were suppressed by anti-LOX-1 antibody, nicotinamide-adenine dinucleotide phosphate oxidase inhibitor apocynin and the Ang II type 1 receptor blocker Losartan, but not by the Ang II type 2 receptor blocker PD123319.(In Vivo):Angiotensin II human (5 mL of 1 nM; intraperitoneal injection; 200-250 g Sprague-Dawley rats) acetate induces a significant neutrophil recruitment that was maximal at 4 hours and had resolved by 24 hours.To distinguish the AT1 receptor population that is critical for the pathogenesis of hypertension, osmotic minipumps are implanted s.c. into each animal to infuse Angiotensin II human (1000 ng/kg/min) acetate continuously for 4 weeks. Angiotensin II human acetate causes hypertension by activating AT1 receptors in the kidney promoting sodium reabsorption.
  • In Vitro
    Most of the known actions of Angiotensin II (Ang II) human acetate are mediated by AT1 receptors, the AT2 receptor contributes to the regulation of blood pressure and renal function. Angiotensin II human acetate raises blood pressure (BP) by a number of actions, the most important ones being vasoconstriction, sympathetic nervous stimulation, increased aldosterone biosynthesis and renal actions. Other Angiotensin II human acetate actions include induction of growth, cell migration, and mitosis of vascular smooth muscle cells, increased synthesis of collagen type I and III in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. These actions are mediated by type 1 Ang II receptors (AT1). Angiotensin II (1 nM) induces the expression of LOX-1 and VEGF and enhances capillary formation from human coronary endothelial cells in Matrigel assay. Angiotensin II -mediated expression of LOX-1 and VEGF, capillary formation, intracellular reactive oxygen species generation, and phosphorylation of p38 as well as p44/42 mitogen-activated protein kinases, were suppressed by anti-LOX-1 antibody, nicotinamide-adenine dinucleotide phosphate oxidase inhibitor apocynin and the Ang II type 1 receptor blocker Losartan, but not by the Ang II type 2 receptor blocker PD123319.
  • In Vivo
    Angiotensin II human (5 mL of 1 nM; intraperitoneal injection; 200-250 g Sprague-Dawley rats) acetate induces a significant neutrophil recruitment that was maximal at 4 hours and had resolved by 24 hours.To distinguish the AT1 receptor population that is critical for the pathogenesis of hypertension, osmotic minipumps are implanted s.c. into each animal to infuse Angiotensin II human (1000 ng/kg/min) acetate continuously for 4 weeks. Angiotensin II human acetate causes hypertension by activating AT1 receptors in the kidney promoting sodium reabsorption.
  • Synonyms
    Angiotensin II human acetate,Ang II acetate,DRVYIHPF acetate
  • Pathway
    Endocrinology/Hormones
  • Target
    RAAS
  • Recptor
    angiotensin AT1?receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    68521-88-0
  • Formula Weight
    1106.2
  • Molecular Formula
    C52H75N13O14
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 25 mg/mL (22.60 mM)
  • SMILES
    CC(O)=O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Fyhrquist F, et al. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995 Nov;9 Suppl 5:S19-24.
molnova catalog
related products
  • L162389

    L162389 is an orally active and potent angiotensin II receptor antagonist with a balanced affinity for AT1 and AT2 receptor subtypes that stimulates the conversion of phosphatidylinositol.

  • Leucylarginylproline

    Leucylarginylproline is an?inhibitor of angiotensin-converting enzyme (ACE) (IC50 : 0.27μM).

  • Prosaikogenin G

    Prosaikogenin G is a compound isolated from the roots of Buleurum bicaule Helm (Apiaceae) and id a derivative of Saikosaponin d in the gastrointestinal tract, exhibiting a significant inhibitory effect on angiotensin II-induced proliferation of mesangial